South Africa's Nuclear Energy Corporation (Necsa) and Quantum Leap Energy (QLE) have signed a binding heads of agreement to create a joint venture that would produce high-assay low-enriched uranium (HALEU) at Pelindaba, the country's main nuclear research site. QLE's parent company, ASP Isotopes, announced the agreement on 15 October 2026.

What the agreement covers

The heads of agreement establishes a commercial framework to develop, finance, build and operate both a test bench and a commercial HALEU production facility. It builds on a November 2024 memorandum of understanding between the two parties and a February 2026 pre-implementation services contract — a sequence that has moved the project from study into binding commercial terms.

Equity, capital and construction roles

Under the agreed principles, QLE will hold roughly 80 percent of the joint venture, lead operations and raise the capital. Necsa will hold about 20 percent and contribute site access, safeguards expertise, and licensing and regulatory support. The parties also intend for Necsa to take on an engineering, procurement and construction (EPC) role, giving the project direct access to its engineering capabilities.

Necsa Group CEO Loyiso Tyabashe said the world needs new, reliable and secure sources of advanced nuclear fuel and that South Africa is well placed to supply them. QLE CEO Ryno Pretorius described the deal as real commercial progress and a step closer to enrichment.

Offtake already lined up

QLE says supply agreements with advanced reactor developer TerraPower already provide offtake for the venture's expected HALEU output — a notable feature for a project that has not yet reached commercial production.

The Pelindaba site

Pelindaba lies about 30 kilometres west of Pretoria and is home to the 20 MW SAFARI-1 research reactor. Work to refurbish the infrastructure that houses the existing test bench is under way, alongside talks with the relevant authorities.

A note of caution

Commercial production remains a development objective rather than a demonstrated capability. ASP Isotopes states that it has not yet applied its enrichment technology to uranium-235, and testing permissions are limited to activities covered by its services contract with Necsa. The test bench programme is therefore the first real indicator of whether the announced timeline holds.

This article was assisted by AI analysis. Please refer to the original source for official information.